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Abstract
Background: Our recent discovery of the substituted cyclobutane Boc5, one of the first non-peptidic agonists at glucagon-
like peptide-1 receptors, offers the potential of combining oral availability with full agonism capable of eliciting antidiabetic
and antiobesity effects. The present study was aimed at determining the in vivo pharmacologic properties of Boc5 in both
normal and diabetic mice following chronic administration, with emphasis on glycemic control and weight loss.
Methodology/Principal Findings: C57BL/6J and db/db mice were treated daily with Boc5 for 4 weeks and a range of
pharmacologic parameters, including hemoglobin A1c, intraperitoneal glucose tolerance, insulin tolerance, fasting insulin
and leptin levels, food intake, body weight and fat mass, were assessed before and after the treatment. Effects on food
intake, gastric emptying, and insulinogenic index were also investigated in animals acutely administered with Boc5. Boc5
(3 mg) was able to induce a durable restoration of glycemic control (normalization of both hemoglobin A1c and
intraperitoneal glucose tolerance) in db/db mice, following 4 weeks of daily administration. As with peptidic glucagon-like
peptide-1 receptor agonists, its glycemic benefit and weight (fat) loss were associated with dose-dependent effects that
included reduction in food intake, slowing of gastric emptying (both of which reduce nutrient-drive at b-cells), stimulation
of insulin secretion (which was glucose-dependent), and elevation in insulin sensitivity. There was little effect on normal
mice treated in the same manner.
Conclusions/Significance: Our findings suggest that Boc5 is the only non-peptidic molecule reported thus far to
simultaneously activate this spectrum of antidiabetic effects.
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Introduction
Metabolic syndrome [1], also known as ‘‘insulin resistance
syndrome’’ and ‘‘syndrome-X’’, embraces a clustering of cardio-
vascular risks that result largely from hypernutrition [2]. The
association of some elements, which include obesity, dysglycemia
(ranging from impaired glucose tolerance through overt diabetes),
dyslipidemia, insulin resistance and hypertension, have been
recognized for 40 years [3,4].
Peptidic glucagon-like peptide-1 (GLP-1) receptor agonists,
exemplified by the first incretin mimetic, exenatide, can ameliorate
several of these elements, including adiposity [5], dysglycemia,
dyslipidemia, insulin resistance and hypertension [6]. They offer
the potential to diminish the cardiovascular sequelae of epidemic
type 2 diabetes mellitus and obesity, now claiming, respectively,
9.3% [7] and 24% of the U.S. population [7,8].
From an insulin-centered viewpoint, glycemic control may be
augmented three ways: (i) reduction of insulin demand: a decrease
in caloric intake, slowing of gastric emptying, reduction in
digestion and/or absorption, and diminished endogenous produc-
tion of glucose (e.g. by suppressing inappropriately elevated
glucagon secretion) will lead to a reduced need for insulin-
mediated nutrient storage; (ii) amplification of insulin secretion,
mediated through both glucose-independent and glucose-depen-
dent mechanisms [9]; and (iii) an increase in insulin sensitivity (loss
of which is a hallmark of metabolic syndrome). Increases in insulin
sensitivity may follow chronic, but not acute, administration of
GLP-1 [10] or exendin-4 [11].
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modes of action. Amylinomimetics excel at reducing glucose
appearance (i above), but are devoid of insulinotropic or direct
insulin-sensitizing effects (ii and iii above) [12]. Sulfonylureas
directly stimulate insulin secretion (ii above), but their glucose-
independent action carries a risk for sometimes-fatal hypoglycemia
[13]. Glucose-dependent insulinotropic peptide (GIP) receptor
agonists powerfully induce glucose-dependent insulin secretion
[14], but have no intrinsic effect on food intake, gastric emptying
[15], glucagon secretion [16], or insulin sensitivity [17]. Insulin-
sensitizing agents, such as the thiazolidinediones (TZD), have
antidiabetic efficacy, but do not reduce nutrient assimilation or
increase insulin secretion, and typically cause weight gain [18].
The benefits of combination therapy with different antidiabetic
agents may derive from apparent advantages of exploring more
than one mode of the effects. GLP-1 receptor (GLP-1R) agonists
are the only agents thus far known to possess all 3 modes in a
single molecule.
All GLP-1R agonists developed to date, or currently under
development, are of peptidic nature and require injection.
Endogenous GLP-1R agonism can be increased sufficiently for
antidiabetic effect by blocking the predominant GLP-1 degrading
enzyme, dipeptidyl peptidase-IV (DPP-IV), resulting in an
elevation of GLP-1 levels [19]. But this increase in agonism
appears insufficient for clinical weight loss [20], and seems to not
fully capture the antidiabetic potential of GLP-1R agonism, as
exemplified by once-weekly injected exenatide (LAR) [21].
Non-peptidic GLP-1R agonists could, in principal, be orally
available and attain such activity. Several screening efforts yielded
leads capable of at least partially activating the GLP-1 signaling
pathway in vitro [22,23]. But none reported an in vivo effect prior to
our recent identification of Boc5, a substituted cyclobutane, as a full
GLP-1R agonist [24]. The purpose of the present study was to
characterize the in vivo pharmacologic properties of Boc5,
determining its potency and efficacy for antidiabetic and weight
loss effects in both non-diabetic and diabetic/obese murine models.
In addition, we interrogated a spectrum of GLP-1 actions to
examine whether Boc5 fully mimicked the response to peptidic
agonists by activating each of the three modes of antidiabetic effects.
In all aspects investigated so far, Boc5 mimics the therapeutic
spectrum associated with peptidic agonists, and can fully or
partially normalize metabolic derangements manifest in db/db
mice. Boc5 may thus represent a chemical scaffold for the
pharmaceutical development of orally available incretin mimetics.
Results
Measures of glycemic control
Boc5 administered for 4 weeks did not lower hemoglobin A1c
(HbA1c) in non-diabetic C57BL/6J (wildtype) mice. In contrast, in
db/db mice, daily injection of Boc5 invoked a dose-dependent
improvement in glycemic control, as assessed by weekly HbA1c
measurement. Reduction in HbA1c was significantly different from
control within 1 week of Boc5 treatment (3 mg), and remained so
until week 14 (10 weeks after stopping treatment). HbA1c indeed
continued to decline after cessation of Boc5 treatment at week 4: it
was minimal at week 7, and was maximally different from control at
week 9; the ED50 for the HbA1c-lowering effect at week 8 was
0.65 mg/day60.13 log. HbA1cin Boc5-treated db/db mice became
statistically indistinguishable from levels in non-diabetic C57BL/6J
mice within 5 weeks of initiating treatment, and remained so for a
further 5 weeks (shown as n.s. in Fig. 1A). Daily oral administration
of Boc5 also decreased HbA1c in diabetic mice but it required a
high dose (3 mg; Supplemental Fig. S1).
Glucose tolerance was quantified as the area-under-the-curve
integrated from 0–120 min (AUC120) after an intraperitoneal
glucose tolerance test (IPGTT). Prior to initiating therapy with
Boc5, db/db mice showed impaired glucose tolerance relative to
non-diabetic C57BL/6J control mice (P,0.0001, ANOVA;
P,0.01 for each db/db dose group vs wildtype, Dunnett’s multiple
comparisons). An IPGTT conducted after 4 weeks of Boc5
treatment revealed a dose-dependent restoration of glucose
tolerance, such that the glucose profile of mice receiving 3 mg/
day Boc5 was indistinguishable from that of non-diabetic C57BL/
6J mice (P=0.90 for AUC120; ED50 0.31 mg/day; Fig. 1B). The
normalization of the glucose profile appeared to reflect reduction
of each, fasting glucose, glucose excursion, and rate of decay of
blood glucose. Effects on fasting glucose and rate of glucose decay
were suggestive of improvements in insulin sensitivity and were
examined further.
Treatment with Boc5 had a major effect upon fasting blood
glucose in db/db mice. Fasting concentrations prior to treatment
were ,12–14 mM in diabetic mice, and in the vehicle-treated
controls, worsened somewhat to ,16 mM over 4 weeks. In
contrast, Boc5 treatment dose-dependently (P,0.0001, ANOVA)
lowered fasting glucose toward the ,5–5.7 mM levels observed in
non-diabetic C57BL/6J mice (3 mg Boc5 response became
indistinguishable from wildtype, Dunnett’s multiple comparisons).
Thus, in contrast to vehicle treated mice where fasting glucose
increased by ,4 mM over 4 weeks, Boc5 treatment resulted in a
reduction of ,8 mM, essentially normalizing fasting glucose in
diabetic db/db mice without evidence of hypoglycemia (the lowest
individual value was 5.3 mM). The ED50 for Boc5-mediated
reduction in fasting glucose was 0.82 mg/day (Fig. 1C). The
change in fasting glucose from pretreatment until measured after 4
weeks Boc5 treatment was assessed for each of 48 mice for which a
data pair was available. The dose response analysis indicated a
dose-dependent fall of up to 14.6 mM glucose, and an ED50 of
0.87 mg/day (Fig. 1D).
Measures of adiposity
Daily Boc5 administration to db/db mice led to a dose-
dependent reduction in body weight, relative to the weight gain
observed in vehicle treated controls. The ,7.5 g relative weight
loss (3 mg/day dose group) amounted to ,16% of the initial 46 g
body weight of the db/db mice (Fig. 2A). Effects on body
composition were examined in further experiments on both db/
db and wildtype C57BL/6J mice treated i.p. for 4 weeks with
vehicle, 1 mg, or 3 mg Boc5 daily. Diabetic db/db mice were
,2.2-fold heavier than wildtype mice, and had ,19-fold more
dissectible fat which contributed to an 8-fold elevation of fat as a
percent of body weight. The fat depots sampled in these
experiments comprised 22% of total body weight in db/db mice.
This was ,42% of the value (5262%) reported for total fat
extracted from db/db mice by chloroform-methanol [25]. The
2.2 g lost from the 4 fat depots after 3 mg/day Boc5 treatment in
the current study may therefore signify a greater amount of total
fat loss (e.g. 5.3 g if proportionate, representing 71% of the 7.5 g
body weight change, relative to controls). While Boc5 invoked
weight loss in db/db mice, it did not in wildtype mice (P=0.0014
and P=0.724, respectively, ANOVA). Similarly, while Boc5
reduced body fat in db/db mice, it did not in wildtype mice
(P=0.0067 and P=0.311, respectively, ANOVA). Although fat as
a percent of total body mass trended downward with increasing
Boc5 dose in db/db mice (P=0.074, ANOVA), there was no
similar trend in wildtype mice (Fig. 2B).
Plasma leptin concentration was measured in db/db mice before
and after 4 weeks treatment with Boc5. Prior to treatment, leptin
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ml and 2.6 ng/ml, respectively, P,0.0001, unpaired t test). Leptin
was markedly reduced by Boc5 (P,0.0001, ANOVA), following
3 mg/day administration, to a value of 58.6 ng/ml, that is 68% of
the pretreatment and 57% of vehicle-treated levels (P,0.0001,
Dunnett’s multiple comparisons) (Fig. 2C).
Measures of nutrient appearance
Of the incretin hormones, only GLP-1 directly limits nutrient
appearance, via inhibition on food intake [26] and gastric
emptying [15]. GLP-1 may further limit glucose appearance
through the suppression of glucagon secretion [27].
Boc5 dose-dependently inhibited food intake by up to 50% at
6 h after acute administration in db/db mice (P,0.002, ANOVA;
ED50 0.91 mg; Figs. 3A and 3B). A similar anorectic effect of Boc5
has been observed in wildtype mice [24]. The absence of Boc5
effect on insulin sensitivity in wildtype mice, reported below,
suggests that its anorexic and insulin-sensitizing effects may be
dissociable. A similar dose-dependent effect of Boc5 to inhibit food
intake in db/db mice by up to 42% endured throughout 4 weeks of
daily administration, as reflected by cumulative intake (Fig. 3C).
Figure 1. Antidiabetic effects of Boc5. (A) Effect of different doses of daily intraperitoneal (i.p.) Boc5 injection from weeks 0–4 on HbA1c in
diabetic db/db mice. (B) Blood glucose profiles during an i.p. glucose challenge after 4 weeks of Boc5 treatment in db/db mice. The glucose area-
under-the-curve integrated from 0–120 min (AUC120) was calculated for each animal before and after Boc5 treatment. (C) Dose response for Boc5
effect on fasting blood glucose after 4 weeks daily i.p. injection. (D) Dose response for changes in fasting blood glucose in individual db/db mice over
4 weeks. In all panels the pink and gray bands respectively denote mean6SD (standard deviation) of values measured in db/db and non-diabetic
C57BL/6J mice (C57) prior to treatment. Symbols are otherwise means6SEM (standard error of the mean). n.s., not statistically significant.
doi:10.1371/journal.pone.0002892.g001
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characterized using a conditioned taste aversion protocol, in which
it was compared to exendin-4 (3 and 6 mg). The selection of a
particular flavor (e.g. grape) was paired with i.p. injection of lithium
chloride, considered aversive, which after 2 training runs, reduced
total or fractional consumption of the paired flavor vs an alternate
(e.g. cherry). Administration of another nauseogenic agent typically
reduces consumption of the paired flavor. Both doses of exendin-4
resulted in a robust conditioned taste aversion (P,0.01, paired t
test), as has been previously reported [28]. Similarly, the 6 mg
(P,0.05, unpaired t test), but not the 1 and 3 mg doses of Boc5
invoked significant conditioned taste aversion (Fig. 3D). This study
was reproduced in diabetic db/db mice in which both lithium
chloride (n=8) and exendin-4 (3 mg, n=8) elicited significant
conditioned taste aversion (P,0.05 and P,0.01, respectively,
paired t test), while Boc5 (3 mg, n=8) appeared to be less effective
(P=0.1347, paired t test; Supplemental Fig. S2).
Gastric emptying was assessed by the appearance in plasma of
tritium derived from 3-[
3H]glucose 15 min after gavage into fed
mice. It has been shown with this label that transport across the
stomach wall is negligible, with absorption only occurring after
release into the small bowel [29]. Boc5 significantly slowed gastric
emptying when administered 1 or more hours before gavage
(Fig. 3E). Boc5 i.p. injected 6 h before gavage dose-dependently
slowed gastric emptying in both db/db and C57BL/6J mice (ED50
2.25 and 1.26 mg, respectively). This effect was equal in
magnitude to a fully inhibitory (1 mg) dose of exendin-4 (Fig. 3F).
Suppression of gastric emptying by 2 mg Boc5 (ED80; i.p. injected
2 h before gavage) could be completed blocked by pretreatment of
C57BL/6J mice with 20 mg exendin(9–39), a selective GLP-1R
antagonist [30] (data not shown).
Measures of insulin secretory response
Boc5 has previously been reported to amplify glucose-induced
insulin secretion from isolated rat islets [24]. A similar concentra-
tion-dependent effect of Boc5 to amplify insulin secretion was
observed in rat insulinoma INS-1E cells co-incubated with 16 mM
glucose for 30 min. Exendin-4 was equieffective, but 2800-fold
more potent in the same assay (data not shown).
Insulin secretory stimulation can be quantified in mice using an
insulinogenic index [31], which describes the relationship between
insulin secretory response and a secretory stimulus, such as glucose
delivered intravenously or intraperitoneally. The slope of the
relationship between quasi-steady-state insulin and glucose
concentrations (or changes in concentration) quantifies the
amplification of secretion typical of incretin action. In the present
study, the insulinogenic index derived from an i.p. glucose
challenge in the presence of vehicle, was increased 3.2-fold by
both Boc5 and exendin-4 (P,0.002, ANOVA; Figs. 4A and 4B).
Boc5 was 2700-fold less potent (on a mass basis) than exendin-4
injected i.p. in the same assay (ED50 0.97 mg and 0.36 mg,
respectively; Fig. 4B), comparable to the potency ratio observed
with INS-1E cells in vitro.
A parallel experiment was performed in 12-h fasted diabetic db/
db mice. While exendin-4 caused a significant and dose-dependent
elevation of insulin secretion after an i.p. glucose challenge (ED50
0.25 mg), acutely injected Boc5 at doses up to 6 mg failed to do so
Figure 2. Antiobesity effects of Boc5. (A) Time course of Boc5
effect on changes in body weight. (B) Fat mass and fat percent of body
weight. (C) Plasma leptin levels following 4-week daily i.p. treatment
with Boc5 in db/db mice.
doi:10.1371/journal.pone.0002892.g002
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doses of Boc5. (B) Dose response for effect on food intake at different times after i.p. administration of Boc5. (C) Time course for chronic effect of Boc5
administered for 4 weeks in db/db mice on cumulative food intake. (D) Effect of Boc5 on conditioned taste aversion (CTA) in C57BL/6J mice. (E) Effect
of Boc5 (3 mg i.p.) on gastric emptying of 3-[
3H]glucose at different times after Boc5 administration in C57BL/6J mice (C57). (F) Dose response for
effect of i.p. Boc5 on gastric emptying measured 6 h after Boc5 administration in both C57 and db/db mice. Band is the effect of fully inhibiting (1 mg)
dose of exendin-4 in the same protocol (mean6SD).
doi:10.1371/journal.pone.0002892.g003
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diabetic animals (data not shown).
Measures of insulin sensitivity in vivo
Chronic GLP-1R agonism has been associated with a marked
increase in insulin sensitivity in rodents [32]. While the physiologic
basis of such an insulin sensitizing effect is still emerging, the effect
may be of therapeutic importance, and was assessed here.
Fasting plasma insulin concentration correlates with insulin
resistance. It was 43-fold elevated in control db/db mice compared
to wildtype C57BL/6J mice (12.97 ng/ml and 0.30 ng/ml,
respectively, P,0.0002, ANOVA). Boc5, without effect upon
fasting plasma insulin concentration in C57BL/6J mice, dose-
dependently reduced it by up to 82% in db/db mice (P,0.0005,
ANOVA; Fig. 4E). HOMAir is an index of insulin resistance that is
derived from fasting glucose and insulin, and correlates inversely
in rodents with insulin sensitivity measured by euglycemic clamp
[33]. HOMAir was 102-fold elevated in vehicle-treated db/db
control mice vs C57BL/6J non-diabetic mice. Again, while Boc5
had no consistent effect in C57BL/6J mice, it dose-dependently
decreased HOMAir by up to 91% in db/db mice (P,0.0008,
ANOVA; Fig. 4F). QUICKI, similarly derived from fasting insulin
and glucose, is an index of insulin sensitivity that correlates with
clamp-derived measures in mice [34]. It was unaffected by Boc5 in
C57BL/6J mice, but was dose-dependently increased by Boc5 in
db/db mice (P,0.0001, ANOVA; Fig. 4G).
Insulin sensitivity after 4 weeks of treatment was assessed in
separate insulin tolerance test experiments by the rate of glucose
lowering in response to exogenous insulin. The overall glucose
response in mice is typically an initial fall in plasma concentration
(attributable to insulin, and subject of this analysis), followed by a
rise (attributable to glucagon and other counter-regulatory
hormones). The initial rate of glucose fall in response to 2 IU/
kg recombinant human insulin (Kitt) was 3.6-fold higher in vehicle-
treated C57BL/6J mice than in db/db controls. Kitt was unaffected
by chronic Boc5 administration in C57BL/6J mice, but was
increased 1.9-fold with Boc5 treatment (3 mg/day) in db/db mice
(P,0.0126, ANOVA; Fig. 4H). Thus, via several independent
methods, Boc5 treatment for 4 weeks was associated with an
increase in insulin sensitivity in insulin-resistant db/db mice, but
not in insulin-sensitive C57BL/6J wildtype mice. This result is
consistent with the changes in insulin sensitivity observed in
rodents following chronic (but not acute) administration of
peptidic GLP-1R agonists [35].
Discussion
The present study examined the in vivo pharmacology of the
substituted cyclobutane Boc5, the first non-peptidic GLP-1R
agonist to show effects in whole animals. In all instances described
above, in both the db/db mouse model of diabetes/obesity, and in
wildtype C57BL/6J mice, Boc5 exhibited actions typical of those
observed with peptidic agonists. Where exenatide (synthetic
exendin-4) was used as a positive control, maximally-stimulating
effects of Boc5 were similar in magnitude to maximally-stimulating
effects of exenatide, albeit the latter being ,3 orders of magnitude
more potent.
Antidiabetic effects
HbA1c is a product of non-enzymatic glycation of hemoglobin.
If red cell/hemoglobin turnover is constant, HbA1c as a fraction
of total hemoglobin is time-weighted function of recent plasma
glucose concentration. The dose-dependent reduction of HbA1c
in db/db mice shown in Fig. 1A is notable on several counts. First,
not only did HbA1c values significantly improve vs vehicle-treated
controls, but indeed, at some time points and doses, entered the
normal range (i.e. were ‘‘normalized’’). This result is consistent
with that reported for rodents chronically administered exenatide
[11], and is reminiscent of clinical data obtained with once-weekly
exenatide, where 86% of patients attained the American Diabetes
Association (ADA) treatment goal HbA1c of 7% (vs 0% for
standard metformin and/or sulfonylurea therapy) [36]. Second,
the glycemic benefit endured beyond the period of treatment, and
was in fact maximal 2–4 weeks after cessation of therapy. This
durable imprint upon the metabolic machinery appears similar to
a ‘‘memory effect’’ reported with GLP-1 administration [37].
Mechanisms underlying glycemic benefit
The blood glucose response to the intraperitoneal glucose
challenge shown in Fig. 1B, obtained in db/db mice 1 day after
the last dose of Boc5, suggests some potential mechanisms of action.
The lowering of fasting glucose exhibited there, and in Figs. 1C and
1D alludes to increases in insulin sensitivity. An elevation in insulin
sensitivitywasfurthersupportedbythedose-dependentreductionin
fasting insulin concentrations displayed in Fig. 4E. Such a decrease
in insulin demand following chronic treatment with Boc5 is in
agreement with previous findings in insulin-resistant obese fa/fa
Zucker rats after 6 weeks of exenatide therapy [32].
Insulin/glucose data pairs enabled the calculation of the
HOMAir and QUICKI indices depicted in Figs. 4F and 4G.
Both have recently been demonstrated to correlate with insulin
sensitivity in mice, as measured by euglycemic clamp [33]. Prior
Boc5 treatment for 4 weeks markedly increased insulin sensitivity,
as exemplified by changes in these indices. The increased rate of
glucose lowering in response to a fixed (2 IU/kg) dose of insulin,
shown in Fig. 4H, provided additional independent evidence for
an insulin sensitizing effect of Boc5 in db/db (but not insulin-
sensitive wildtype) mice.
While GLP-1 agonists have no acute effect upon whole-body
insulin sensitivity [38,39], or in muscle or fat [35], chronic GLP-
1R agonism exerts an insulin-sensitizing effect in humans [40] and
rodents [10,35]. The insulin-sensitizing effects of Boc5 observed
here is consistent with the response to chronic GLP-1R agonism.
A leptin-mediated feedback that limits lipotoxicity by confining
triglyeride to adipocytes [41] may be overwhelmed in hypernu-
trition. In these circumstances, insulin resistance is associated with
Figure 4. Effects of Boc5 on insulin secretion and insulin sensitivity. (A) Effect of prior administration of Boc5 on insulinogenic index, the
slope of the relationship between plasma insulin and blood glucose concentrations in quasi-steady-state, during the decay phase of an
intraperitoneal (i.p.) glucose challenge in fasted C57BL/6J (C57) mice. (B) Dose response for effects of Boc5 and exendin-4 on insulinogenic index in
C57 mice during an i.p. glucose challenge. (C) Effect of prior administration of exendin-4 and Boc5 on insulinogenic index in fasted db/db mice. Gray
band depicts the slope range of different Boc5 doses (0.3, 1, 3 and 6 mg). (D) Dose response for effects of Boc5 and exendin-4 on insulinogenic index
in db/db mice during an i.p. glucose challenge. (E) Dose response for effect of 4-week prior administration of Boc5 on fasting insulin concentrations in
db/db (open circles) and non-diabetic C57 mice (closed circles). (F) Dose response for effect of Boc5 on HOMAir, an index of insulin resistance derived
from fasting insulin and glucose concentrations. (G) Dose response for effect of 4-week prior Boc5 administration on QUICKI, an alternate index of
insulin sensitivity derived from fasting insulin and glucose concentrations. (H) Effect of 4-week administration of Boc5 (3 mg/day) on Kitt, a measure of
insulin-mediated glucose clearance, in C57 and db/db mice.
doi:10.1371/journal.pone.0002892.g004
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liver and b-cells. An anti-lipogenic potential of GLP-1 is suggested
by its inhibition of nutrient assimilation and by an association with
higher rates of fat oxidation and energy expenditure in humans
[42]. Such an effect in liver is further evidenced by reversal of
hepatic steatosis and oxidative stress in ob/ob mice following
exenatide treatment [43], and is supported in type 2 diabetic
patients by amelioration of surrogate markers of nonalcoholic fatty
liver disease [44]. The coincidence in the present study of a
restoration of insulin sensitivity and of a reduction in leptin
concentration (towards a modulable range) would fit with an anti-
lipogenic effect of Boc5 to restore triglyceride homeostasis.
Cellular evidence for such an action will be the basis of future
studies.
The GLP-1 action that first identified it as a drug target was its
amplification of glucose-dependent insulin secretion [9]. Even
though plasma insulin is typically reduced by exogenous GLP-1R
agonists through their several glucose-lowering actions, amplifica-
tion of insulin secretion can be revealed with indices such as
HOMA-B [45] and the insulinogenic index [46]. The effects of
Boc5 shown in Figs. 4A and 4B to treble the insulinogenic index
directly support an incretin agonist action. The maximal effect of
Boc5 was similar to that of exenatide observed in the same
experimental protocol. Likewise, the insulin/glucose regression
lines of various Boc5 doses intersected with the X-axis (glucose) at
,5 mM. That is, insulin secretion ceased at plasma glucose
concentrations below ,5 mM, implying preservation with Boc5 of
the characteristic over-ride of insulin stimulation during hypogly-
cemia [47].
An abnormal plasma insulin response to the i.p. glucose
challenge was observed in either saline- or vehicle-treated diabetic
db/db mice (Fig. 4C), consistent with previously findings reported
in the literature [48,49]. Such a reduced capacity for insulin
secretion was shown to be associated with a decrease in pancreatic
insulin storage [48]. Acute treatment with exenatide, but not Boc5,
dose-dependently stimulated insulin secretion (Fig. 4C) with a 7.2-
fold increase in the insulinogenic index (Fig. 4D) compared to a
3.2-fold increase in C57BL/6J mice (Fig. 4B). The inability of
acutely administered Boc5 to elicit insulin responses under
hyperinsulinemia may result from its poor potency as the
compound is approximately 2700 times less potent than exenatide
(Fig. 4B).
Gastric emptying, only recognized as being of glucoregulatory
significance comparatively recently [50], is slowed by several meal-
related peptides, including GLP-1, secretin, amylin and cholecys-
tokinin [15]. The data shown in Figs. 3E and 3F affirm an effect of
Boc5 to dose-dependently slow gastric emptying in both db/db and
wildtype mice, with a maximal effect similar to that of exenatide in
the same protocol. Like lithium chloride and exenatide, Boc5 at a
higher dose (6 mg) induced conditioned taste aversion in C57BL/
6J mice (Fig. 3D). This tendency was also observed in db/db mice
treated with 3 mg Boc5 although the effect was not statistically
significant (Supplemental Fig. S2). Such a satiety action exerted by
Boc5 provides further evidence that this molecule works as a true
GLP-1 mimetic in vivo.
Antiobesity effects
As with peptidic GLP-1R agonists [26], Boc5 administration
dose-dependently reduced both acute (Figs. 3A and 3B) and
chronic (Figs. 3C) food intake. We surmise that food intake
inhibition with Boc5 is important to its dose-dependent reduction
(or slowing of gain) in body weight shown in Figs. 2A. For an ideal
antiobesity therapy, it is preferred that the weight loss is
predominantly from fat. Analysis of carcasses from mice
chronically treated with Boc5 indicated that in db/db mice, mass
was preferentially lost from fat, while in lean wildtype mice treated
in the same manner, fat mass was preserved. This was associated
with a dose-dependent decrease in fat as a percent of body weight
(Fig. 2B). Plasma leptin is a signal derived from fat-replete
adipocytes, and is considered a homeostatic effector of body
energy content [51]. The marked reduction in db/db mice of
plasma leptin concentration towards normal with Boc5 treatment
(3 mg/day), as shown in Fig. 2C, was consistent with fat loss.
It was notable in the present study, that the Boc5 efficacy for
glycemic control (ED50 values between 0.3 and 1 mg/day) was
generally greater than for weight loss (daily dose of 3 mg). This is
in agreement with the preclinical and clinical experience with a
number of agents acting upon the GLP-1 axis (incretin mimetics
and DPP-IV inhibitors), wherein weight loss is more difficult to
achieve than glycemic control [52].
Pharmaceutic implications
Therefore, in all aspects thus-far investigated, Boc5 is a true
mimetic of peptidic GLP-1R agonists. A potential advantage of
small molecule organics such as Boc5 over peptidic agonists is the
ability to survive the proteolytic environment of the gut, thereby
permitting oral availability. This has yet to be fully realized with
Boc5 or its analogues, possibly through improvement of their oral
bioavailability. Another attractive feature over the already-
marketed orally-available DPP-IV inhibitor drugs, demonstrated
in the present study, is the attainment of full GLP-1R agonism.
DPP-IV inhibitors can invoke clinically meaningful antidiabetic
effect through elevation of endogenous GLP-1, and perhaps other
regulatory peptides. But they appear to be incapable, even with
near-total inhibition of DPP-IV enzymatic activity, of generating
sufficient GLP-1 action to invoke weight loss [52]. Boc5, which
exhibits both antidiabetic and weight loss effects, may thus
represent a starting point for a new class of oral agents targeting
metabolic diseases.
Materials and Methods
Animals
Eight-week-old C57BL/6J mice of both sexes (22–25 g;
Shanghai SLAC Laboratory Animal Co., Shanghai, China) and
eight-week-old C57BL/6J-m+/+ Lepr
db (db/db) mice of both sexes
(the Model Animal Research Center of Nanjing University,
Nanjing, China) were housed at 22.760.8uC in a 12:12 h
light:dark cycle and were fed and watered ad libitum. Animal
experimentation was conducted in accordance with regulations
approved by the Animal Care and Use Committee, Shanghai
Institute of Materia Medica, Chinese Academy of Sciences.
Chronic in vivo studies
db/db mice were confirmed as diabetic and assigned into 5
treatment groups (n$8 per group) with matched HbA1c (Glycosal
HbA1c kit, Bio-Rad Laboratories Inc., Hercules, CA and DS1
Glycosal HbA1c Analyzer, Drew Scientific, Barrow in Furness,
U.K.), body weight and sexes. A parallel study with the same
treatment regimen was carried out in non-diabetic C57BL/6J
mice of both sexes (n$6 per group) for comparison. They were
injected i.p. or gavaged once daily with 0 (vehicle control), 0.1, 0.3,
1 or 3 mg Boc5 (1% DMSO, 20% PEG400 in saline, pH 7.4,
0.5 ml) for 4 (i.p. route) or 6 weeks (oral route; n=7 per group).
Blood samples were collected from either the eye socket or the tail
vein. HbA1c and overnight fasting blood glucose (using a Freestyle
Mini
TM blood glucose monitoring system; Abbott Diabetes Care
Inc., Alameda, CA) were assayed weekly, and food intake and
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each animal was fasted overnight, measured for plasma insulin
levels and challenged i.p. with 2 g/kg D-glucose (Sigma-Aldrich,
St. Louis, MO; intraperitoneal glucose tolerance test, IPGTT)
followed by serial sampling of blood glucose. A terminal sample
was taken for determination of leptin concentrations in treated
mice.
In a separate study using an insulin tolerance test (ITT) to assess
insulin sensitivity, both db/db and C57BL/6J mice were chroni-
cally treated with Boc5 for 4 weeks, as described above (n$6 per
group). The insulin tolerance tests, similar to those developed for
clinical use [53], comprised a 2 IU/kg i.p. challenge with
recombinant human insulin (HumulinH R, Lilly Egypt, Giza,
Egypt) followed by glucose sampling at 30 min intervals. The rate
of insulin-mediated fall in plasma glucose was quantified in each
animal by least-squares fit of consecutive non-rising glucose values
to a single-component exponential decay (Prism version 5,
GraphPad Software, CA, San Diego) to derive an initial rate, Kitt.
At the end of the study, mice were sacrificed to dissect and
weigh white fat pads (mesenteric, gonadal, retroperitoneal and
inguinal) and brown adipose tissue. Weights were summed and
expressed as a fraction of total body weight.
Acute in vivo studies
Overnight-fasted db/db mice of both sexes were injected i.p.
with vehicle or 0.1, 0.3, 1 or 3 mg Boc5 formulated as above
(n$10 per group). Individually caged mice were exposed to a pre-
weighed food pellet, which was then reweighed every 15 or 30 min
for 6 h to determine cumulative intake. Insulinotropic actions of
Boc5 and exendin-4 (Sigma-Aldrich) were measured in 4-h fasting
C57BL/6J male and 12-h fasting db/db mice 10 min (exendin-4 at
doses of 0.01, 0.1, 1 and 10 mg) or 6 h (Boc5 at doses of 0.3, 1, 3
and 10 mg) after i.p. administration (n$6 per group). Glucose and
insulin levels were assessed between 0 and 120 min upon an i.p.
glucose challenge (IPGTT) as above.
Gastric emptying
Rates of emptying were assessed from the appearance in plasma
of gavaged labeled glucose, which is not absorbed until it passes
the stomach. The method was a derivation of that developed in
rats [29]. Pilot studies performed to determine the time course of
gastric label release and absorption indicated that blood sampling
15 min after gavage was optimal.
Subsequent studies examined the interval between Boc5 dosing
and the assessment of gastric emptying. Conscious and fed male
C57BL/6J mice were divided into Boc5 or vehicle treated groups
for each time point (n$12). At 0 h, they were injected i.p. with
3 mg Boc5 formulated as above or vehicle. 3-[
3H]glucose (1 mCi
in 0.5 ml distilled water; GE Healthcare, Piscataway, NJ) was
gavaged 0.5, 1, 2, 4, 6 h following the treatment and blood from
an orbital bleed was collected 15 min later for measurement of
plasma tritium activity using a Microbeta scintillation counter
(PerkinElmer, Boston, MA).
Dose-response for the effect of Boc5 treatment was then assessed
at the time-point (6 h) where differences from vehicle-treated mice
were greatest. Dose-response studies in both C57BL/6J (n=12)
and db/db mice (n=14) used Boc5 doses of 0, 1, 3 or 6 mg
administered 6 h before gavage with 3-[
3H]glucose. Exendin-4
(1 mg in 0.1 ml saline, n=6), used as a positive control, was
injected i.p. 10 min before gavage with 3-[
3H]glucose.
Finally, the specificity of Boc5 to suppress gastric emptying was
examined with a GLP-1R selective antagonist, exendin(9–39) (Ana
Spec, San Jose, CA). C57BL/6J mice as above were assigned to
vehicle, Boc5 or Boc5 plus exendin(9–39) treatment groups (n$8).
Boc5 (2 mg) or vehicle was given i.p. 2 h and exendin(9–39) (20 mg
in 0.1 ml saline) 1 h before gavage with 3-[
3H]glucose.
Conditioned taste aversion
Male C57BL/6J mice (7–8 weeks old) or diabetic db/db mice (8–
10 weeks old) were individually housed and subjected to a training
schedule for 5 days, during which they were presented with two
water bottles at the same time (9:30–11:00 AM) for 1.5 h each day
followed by an i.p. injection of saline (2% of body weight). Animals
were randomly grouped (n$8 per group) based on their body
weight at the end of training. On Conditioned Day 1, the water
was replaced with two bottles of either cherry or grape Kool-Aid
(Kraft Foods North America Inc., Rye Brook, NY) as ‘‘Flavor 1’’
[0.15% saccharin (Sigma-Aldrich) with 0.05% Kool-Aid] for
1.5 h. The following day was a Rest Day, in which animals were
only given water for 1.5 h. In the above two days, i.p. injection of
2% body weight of saline was paired with both Flavor 1 and water.
On Conditioned Day 2, each mouse was given an alternative
Kool-Aid as ‘‘Flavor 2’’ (grape or cherry, respectively) for 1.5 h
and was immediately weighed thereafter, injected i.p. with either
2% body weight of saline, 0.15 M LiCl (Sigma-Aldrich), 0.1 ml of
exendin-4 (3 mgo r6mg), 0.5 ml of vehicle solution (1% DMSO
and 20% PEG400 in saline) or 0.5 ml of the vehicle solution
containing 1 mg, 3 mg or 6 mg Boc5. Another Rest Day was
followed and this 4-day conditioned taste course was then repeated
once. On the Test Day, mice were simultaneously given both
flavors in two bottles for 1.5 h with a position alternation after
45 min, and the fluid intake was measured subsequently.
Conditioned taste aversion was signified by either the change in
flavor volume or preference ratio [(Flavor 2 consumption/total
consumption)6100%] [54].
Clinical chemistry
Fasting plasma insulin and leptin levels were analyzed using
respective ELISA kits (EXRMI-13K and EZML-82K) supplied by
Linco Research (St. Charles, MO).
Data analysis
Dose- and concentration-responses were analyzed using Prism
version 5 (GraphPad) to fit 4-parameter sigmoid functions.
General effects were tested using 1-way ANOVA. Except where
noted otherwise, pair-wise comparisons were performed using
Dunnett’s test for multiple comparisons, and t tests for simple pairs
(InStat 3, GraphPad). Data throughout are stated as means6SEM
unless otherwise specified. Two-tailed significance was tested at
a=0.05. Where possible, experiments were designed with a
sample size calculated from preliminary data to yield a power of
B=0.8.
Supporting Information
Figure S1 Effect of different doses of daily oral Boc5
administration from weeks 0–6 on HbA1c in diabetic db/db mice
(n=7 per dose group).
Found at: doi:10.1371/journal.pone.0002892.s001 (0.70 MB TIF)
Figure S2 Effect of Boc5 on conditioned taste aversion (CTA) in
diabetic db/db mice (n=8 per dose group)
Found at: doi:10.1371/journal.pone.0002892.s002 (0.57 MB TIF)
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